



ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

AMGEN IN SINGAPORE

Amgen's local footprint reinforces its commitment to Singapore and is a testament to Singapore's strong track record for best-in-class biopharmaceutical manufacturing. To-date, Amgen has invested more than SGD\$400 million into its Singapore operations.

2014: Heralding the Next-Generation of Biomanufacturing

Amgen's groundbreaking Next-Generation Biomanufacturing facility, opened in Tuas Biomedical Park. It is the first-of-its-kind manufacturing facility that uses the latest innovations and multiple technologies to achieve greater speed, productivity and flexibility in commercial-scale manufacturing. Built in half the construction time and at approximately one quarter of the capital cost, this facility boasts a significantly smaller manufacturing footprint and higher environmental efficiencies with less water and energy consumed and carbon emitted. In less than 2.5 years, the facility has successfully achieved regulatory approvals to produce biologic medicines from various major international regulatory bodies.

2015: Growing Commercial and Manufacturing Capabilities to Serve Patients in Singapore and Beyond

Amgen established its commercial presence to serve patients suffering from serious illnesses in Singapore. Partnering local governmental bodies and the community, the affiliate team drives Amgen's commercial business development, marketing and sales efforts. This ensures that our innovative biopharmaceuticals reach patients, payers and physicians, while proactively supporting programs to address healthcare challenges.

Amgen's first commercial chemical synthesis manufacturing facility located at Tuas Biomedical Park was also opened in the same year. This facility has since achieved regulatory approvals from various major international regulatory bodies in 2019.

2018: Developing Capacity and Capabilities to Support Amgen's Growth

With its focus to become more agile and patient-focused, Amgen opened a new manufacturing support office – the NextGen Workplace that is designed to inspire innovation and collaboration, enhance productivity and to build a vibrant work culture to support its growth in Singapore. Located at Tuas Biomedical Park and spanning more than 7,500 square meters, the NextGen Workplace plays a pivotal role in attracting and retaining talented staff as it supports Amgen's revolutionary NextGen Biomanufacturing and its Chemical Synthesis manufacturing facilities.

AMGEN MISSION

To serve patients

AMGEN QUICK FACTS

[Global Headquarters](#)
Thousand Oaks, California

[Staff](#)
Approximately 24,000 worldwide
More than 400 staff in Singapore

[Stock Listing](#)
NASDAQ: AMGN

[2020 Financial Highlights](#)
Total revenue: \$25.4 billion
Product Sales: \$24.2 billion
R&D expense: \$4.1 billion

[Amgen Singapore Leadership](#)
Emily Razaqi, Vice President
Site Operations, Singapore Manufacturing

Eric Ng
Country Head Singapore-Malaysia
Executive Director, General Manager South East Asia (SEA), Hong Kong, India

[Amgen Singapore Manufacturing](#)
1 Tuas View Drive, Singapore 637026
Tel: +65 6675 0600

[Amgen Biotechnology Singapore Pte Ltd](#)
3 Fraser Street, #15-26/27
DUO Tower, Singapore 189352
Tel: +65 6800 0800 | Fax: +65 6491 5257

Investments in Singapore

- Next-Generation Biomanufacturing Facility
- Chemical Synthesis API Manufacturing Facility
- Manufacturing Support Building
- Commercial Affiliate

Products in Singapore

- AMGEVITA™ (biosimilar adalimumab)
- BLINCYTO® (blinatumomab)
- KYPROLIS® (carfilzomib)
- NEULASTIM® (pegfilgrastim)
- NEUPOGEN® (filgrastim)
- PARSABIV® (etelcalcetide)
- PROLIA® (denosumab)
- REPATHA® (evolocumab)
- VECTIBIX® (panitumumab)
- XGEVA® (denosumab)

A REVOLUTIONARY APPROACH TO BIOMANUFACTURING

With a footprint of just 120,000 square feet (16 percent the size of a conventional facility), Amgen's Next-Generation Biomanufacturing facility in Singapore incorporates multiple innovative technologies into a single facility for commercial manufacturing.

The benefits of next-generation biomanufacturing are immense. The facility adopts a highly flexible, modular design which can be replicated in future facilities, enabling Amgen to increase production capabilities reliably with greater speed, productivity and flexibility. By enabling it to easily switch between different types of equipment to produce different drug substances, this eliminates costly and complex retrofitting inherent in standard facilities. This allows Amgen to respond to changing demands with greater agility, ultimately impacting the speed at which a drug is available for patients. Yielding the same outputs as a conventional plant, its modular single-use bioreactors are capable in accelerating technology transfer to greatly reduce the time and expense needed to scale up new processes for transference from smaller pilot plants to commercial manufacturing plants.

The facility's compact design and the use of the single-use technologies in its operations equally reduces environmental impact significantly when compared to a conventional facility. 21 months after its opening, the Next-Generation Biomanufacturing facility in Singapore received its first Good Manufacturing Practice certification from Singapore's Health Sciences Authority (HSA). Facility and product licensure was obtained within 30 months of opening from major international regulators including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada and ANVISA (Brazil).

TALENT DEVELOPMENT AND COMMITMENT TO GROOM SINGAPORE'S BIOMEDICAL INDUSTRY

Amgen Singapore's investments are strategically aligned with Singapore's Economic Development Board (EDB)'s focus to develop and provide quality biomedical careers for the Singapore workforce. To groom a future-ready workforce to transform the promise of science and biotechnology into therapies that fulfil our mission to serve patients around the world, Amgen Singapore supports the building of a pipeline of skilled specialists for Singapore's biologics manufacturing industry through industry manpower development programs such as Development and Apprenticeship (DNA) and Local BOOST (Local Biologics Skills Training) in collaboration with the Singapore Economic Development Board, SkillsFuture Singapore (SSG), Workforce Singapore (WSG) and Singapore Polytechnic (SP). Since 2014, Amgen Singapore has grown its workforce by more than 450% to over 350 employees.

AMGEN FOUNDATION

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators and invest in strengthening communities where Amgen staff members live and work. In 2017, Amgen Foundation launched the Amgen Biotech Experience in Singapore in collaboration with the Science Center Singapore to provide local mainstream secondary teachers and students with professional development research-grade equipment and hands-on curriculum to transform biology education and to spark students' love for science and discovery. To provide undergraduates in Singapore with the opportunity to engage in cutting-edge research experiences at world-leading institutions to learn about biotechnology, the Amgen Scholars program was likewise launched in 2017. Amgen Scholars has since expanded its program in 2018 and has extended the program to reach undergraduates in Singapore and across Asia in collaboration with the National University of Singapore (NUS).

Amgen's Next-Generation Biomanufacturing compared to conventional manufacturing:

Achieved in Singapore



Awards and Recognition

Singapore Best Workplaces (Ranked #5) and Best Workplaces in Asia (Ranked #23) by Great Place to Work Institute



Great Place to Work® and Great Place to Learn™ Certifications



Best Employers 2020 by Straits Times



Singapore SkillsFuture Employer Award



Workplace Safety and Health Award (Silver) by Workplace Safety and Health (WSH) Council

Champions of Good 2020 by National Volunteer & Philanthropy Centre (NVPC)



AmCham CARES 2021 High Distinction Award by AmCham Singapore



For more information on our pipeline and therapies, visit www.amgen.com | www.amgen.com.sg

Click on links to learn more:

[The Next Generation of Biomanufacturing](#)
[Amgen Biotech Experience \(Singapore\)](#)
[Amgen Scholars \(Singapore\)](#)